Novavax leases new lab for vaccine production

Novavax, Inc., recently announced that it has entered into a long term lease agreement for two facilities in Gaithersburg, Maryland, with 74,000 square feet of laboratory and office space.

The main facility is intended to become the primary commercial-scale plant for vaccine production after minor modifications are finished sometime in mid-2012. Novavax’s commercial headquarters will be located in a nearby facility. Currently, Novavax's pilot-scale operations are located in a production facility near its headquarters in Rockville, Maryland.

"This state-of-the-art facility ideally meets our process requirements and will provide twice the cGMP production capacity of our current facility," Stanley C. Erck, the president and CEO of Novavax, said. "We anticipate that it will enable us to supply our vaccines, most immediately our seasonal and pandemic VLP influenza vaccines, to meet our projected clinical- and commercial-supply requirements for the foreseeable future.

“In addition to cGMP facilities, these buildings will accommodate current and future clinical, R&D and administrative requirements. The company is assessing its long-term needs for the pilot-scale facility, however, I am delighted to report that the very favorable terms of this new lease would allow us to operate both this new facility and our pilot-scale facility at no additional expense over the next several years."

The laboratory, office and manufacturing space is currently owned and operated by Alexandra Real Estate Equities, Inc.